HRP20110698T1 - Kompleks nukleinske kiseline i pripravak za oslobađanje nukleinske kiseline - Google Patents
Kompleks nukleinske kiseline i pripravak za oslobađanje nukleinske kiseline Download PDFInfo
- Publication number
- HRP20110698T1 HRP20110698T1 HR20110698T HRP20110698T HRP20110698T1 HR P20110698 T1 HRP20110698 T1 HR P20110698T1 HR 20110698 T HR20110698 T HR 20110698T HR P20110698 T HRP20110698 T HR P20110698T HR P20110698 T1 HRP20110698 T1 HR P20110698T1
- Authority
- HR
- Croatia
- Prior art keywords
- nucleic acid
- release
- preparation
- carrier
- branched cyclic
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 title claims abstract 31
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract 31
- 102000039446 nucleic acids Human genes 0.000 title claims abstract 31
- 239000000203 mixture Substances 0.000 title claims 2
- 125000004122 cyclic group Chemical group 0.000 claims abstract 10
- 229920001353 Dextrin Polymers 0.000 claims abstract 6
- 239000004375 Dextrin Substances 0.000 claims abstract 6
- 235000019425 dextrin Nutrition 0.000 claims abstract 6
- 229920001503 Glucan Polymers 0.000 claims abstract 2
- 238000006116 polymerization reaction Methods 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- -1 aliphatic primary amine Chemical class 0.000 claims 1
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Nanotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007291317 | 2007-11-08 | ||
| PCT/JP2008/070642 WO2009061003A2 (en) | 2007-11-08 | 2008-11-06 | Nucleic acid complex and nucleic acid delivery composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110698T1 true HRP20110698T1 (hr) | 2011-10-31 |
Family
ID=40303461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110698T HRP20110698T1 (hr) | 2007-11-08 | 2011-09-29 | Kompleks nukleinske kiseline i pripravak za oslobađanje nukleinske kiseline |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8338584B2 (ja) |
| EP (1) | EP2217208B1 (ja) |
| JP (1) | JP5340282B2 (ja) |
| KR (1) | KR101567108B1 (ja) |
| CN (1) | CN101854918B (ja) |
| AR (1) | AR069224A1 (ja) |
| AT (1) | ATE522201T1 (ja) |
| AU (1) | AU2008325504B2 (ja) |
| BR (1) | BRPI0819187A2 (ja) |
| CA (1) | CA2704236C (ja) |
| CO (1) | CO6280469A2 (ja) |
| CY (1) | CY1112029T1 (ja) |
| DK (1) | DK2217208T3 (ja) |
| ES (1) | ES2369869T3 (ja) |
| HK (1) | HK1142278A1 (ja) |
| HR (1) | HRP20110698T1 (ja) |
| IL (1) | IL205237A0 (ja) |
| MX (1) | MX2010005094A (ja) |
| MY (1) | MY149917A (ja) |
| NZ (1) | NZ584841A (ja) |
| PL (1) | PL2217208T3 (ja) |
| PT (1) | PT2217208E (ja) |
| RU (1) | RU2465009C2 (ja) |
| SI (1) | SI2217208T1 (ja) |
| TW (1) | TWI426922B (ja) |
| UA (1) | UA97559C2 (ja) |
| WO (1) | WO2009061003A2 (ja) |
| ZA (1) | ZA201002845B (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI428135B (zh) | 2007-03-26 | 2014-03-01 | Hirofumi Takeuchi | And a carrier composition for quick-acting nucleic acid delivery |
| AR083445A1 (es) | 2010-10-14 | 2013-02-27 | Univ Mie | siARN CONTRA LA FIBROSIS |
| CA2822161C (en) * | 2010-12-29 | 2018-05-29 | Philipp Hadwiger | Small molecule conjugates for intracellular delivery of nucleic acids |
| EP2825565B1 (en) * | 2012-03-15 | 2019-04-03 | Aziende Chimiche Riunite Angelini Francesco A.C.R. | Glycogen-based cationic polymers |
| US20200363389A1 (en) * | 2017-12-27 | 2020-11-19 | Konica Minolta, Inc. | Method for Assessing Medicine |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01238537A (ja) * | 1988-03-18 | 1989-09-22 | Toyo Jozo Co Ltd | 肝障害治療剤 |
| JP3150266B2 (ja) * | 1994-04-01 | 2001-03-26 | 江崎グリコ株式会社 | 環状構造を有するグルカンおよびその製造方法 |
| JP3107358B2 (ja) | 1994-09-13 | 2000-11-06 | 江崎グリコ株式会社 | 環状構造を有するグルカンおよびその製造方法 |
| US6248566B1 (en) * | 1994-09-13 | 2001-06-19 | Ezaki Glico Co., Ltd. | Glucan having cyclic structure and method for producing the same |
| US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5827697A (en) * | 1995-03-31 | 1998-10-27 | Ezaki Glico Co., Ltd. | Process for preparing glucans having a cyclic structure |
| US20030092180A1 (en) | 2001-08-27 | 2003-05-15 | David Lewis | Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo |
| JPH11292795A (ja) | 1998-04-02 | 1999-10-26 | Yamanouchi Pharmaceut Co Ltd | Ｈｉｖコファクター抑制剤 |
| ATE383331T1 (de) | 1998-11-12 | 2008-01-15 | Invitrogen Corp | Transportreagentien |
| JP2005527639A (ja) * | 2001-11-02 | 2005-09-15 | インサート セラピューティクス インコーポレイテッド | Ｒｎａ干渉の治療的利用のための方法及び組成物 |
| RU2289585C2 (ru) * | 2002-02-04 | 2006-12-20 | Корикса Корпорейшн | Новые аминоалкилглюкозаминидфосфатные соединения, иммуностимулирующая фармацевтическая композиция, их содержащая, и способ индуцирования иммунного ответа |
| AU2003299531A1 (en) * | 2002-08-05 | 2004-06-07 | University Of Massachusetts | Compounds for modulating rna interference |
| US20060030578A1 (en) * | 2002-08-20 | 2006-02-09 | Neopharm, Inc. | Pharmaceutically active lipid based formulation of irinotecan |
| US7780873B2 (en) * | 2004-02-23 | 2010-08-24 | Texas A&M University System | Bioactive complexes compositions and methods of use thereof |
| WO2006097725A2 (en) * | 2005-03-15 | 2006-09-21 | Queen Mary & Westfield College | Pharmaceutical compositions comprising microparticles for delivery into neurons |
-
2008
- 2008-06-11 UA UAA201007049A patent/UA97559C2/uk unknown
- 2008-11-05 TW TW097142679A patent/TWI426922B/zh not_active IP Right Cessation
- 2008-11-06 AU AU2008325504A patent/AU2008325504B2/en not_active Ceased
- 2008-11-06 US US12/741,457 patent/US8338584B2/en active Active
- 2008-11-06 DK DK08848047.0T patent/DK2217208T3/da active
- 2008-11-06 MX MX2010005094A patent/MX2010005094A/es active IP Right Grant
- 2008-11-06 EP EP08848047A patent/EP2217208B1/en active Active
- 2008-11-06 JP JP2010517212A patent/JP5340282B2/ja not_active Expired - Fee Related
- 2008-11-06 KR KR1020107012581A patent/KR101567108B1/ko not_active IP Right Cessation
- 2008-11-06 WO PCT/JP2008/070642 patent/WO2009061003A2/en active Application Filing
- 2008-11-06 CN CN2008801151656A patent/CN101854918B/zh not_active Expired - Fee Related
- 2008-11-06 ES ES08848047T patent/ES2369869T3/es active Active
- 2008-11-06 NZ NZ584841A patent/NZ584841A/en not_active IP Right Cessation
- 2008-11-06 BR BRPI0819187 patent/BRPI0819187A2/pt not_active IP Right Cessation
- 2008-11-06 SI SI200830383T patent/SI2217208T1/sl unknown
- 2008-11-06 PL PL08848047T patent/PL2217208T3/pl unknown
- 2008-11-06 PT PT08848047T patent/PT2217208E/pt unknown
- 2008-11-06 MY MYPI2010001775A patent/MY149917A/en unknown
- 2008-11-06 RU RU2010123168/15A patent/RU2465009C2/ru not_active IP Right Cessation
- 2008-11-06 AT AT08848047T patent/ATE522201T1/de active
- 2008-11-06 CA CA2704236A patent/CA2704236C/en not_active Expired - Fee Related
- 2008-11-07 AR ARP080104877A patent/AR069224A1/es unknown
-
2010
- 2010-04-22 IL IL205237A patent/IL205237A0/en unknown
- 2010-04-22 ZA ZA2010/02845A patent/ZA201002845B/en unknown
- 2010-06-08 CO CO10068754A patent/CO6280469A2/es active IP Right Grant
- 2010-09-17 HK HK10108878.8A patent/HK1142278A1/xx not_active IP Right Cessation
-
2011
- 2011-09-29 HR HR20110698T patent/HRP20110698T1/hr unknown
- 2011-11-14 CY CY20111101091T patent/CY1112029T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110698T1 (hr) | Kompleks nukleinske kiseline i pripravak za oslobađanje nukleinske kiseline | |
| HRP20190878T1 (hr) | Modificirane aminokiseline koje sadrže azidnu grupu | |
| BR0108080A (pt) | Preparação de formas de dosagem de solução clara aquosa com ácidos biliares | |
| BR112014010050A8 (pt) | derivados de aminoácido funcionalizados na terminação n capazes de formar microesferas de encapsulação de fármaco | |
| JP2011057686A5 (ja) | ||
| ES2596241T3 (es) | Polímero para el cuidado del cabello | |
| BRPI0820308B8 (pt) | composição farmacêutica compreendendo oxi-hidróxido de ferro em alta carga, seus usos e seus processos de preparação, e comprimido | |
| BRPI0611872B8 (pt) | reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica | |
| WO2009095479A3 (en) | Prodrug comprising a self-cleavable linker | |
| MX2012002502A (es) | Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos. | |
| BR112013016772B8 (pt) | compostos, uso do composto e composição farmacêutica | |
| ATE544444T1 (de) | Zusammensetzungen für die nasale abgabe | |
| RS54578B1 (en) | PREPARED FOR THE TARGETED DELIVERY OF SIRNK | |
| BRPI0419213A (pt) | formas secas de formulação de dosagem de ácido biliar solubilizada aquosa: preparação e usos destas | |
| TR200806298A2 (tr) | Farmasötik formülasyon | |
| WO2008141107A3 (en) | Compositions that include a hydrophobic compound and a polyamino acid conjugate | |
| CN108635590B (zh) | 一种pH响应的多糖–硼替佐米纳米球及其制备方法和应用 | |
| CN104119479B (zh) | 具有细胞膜结构仿生的两亲性接枝聚合物及其制备方法 | |
| Yamabe et al. | Binding inhibition of various influenza viruses by sialyllactose-modified trimer DNAs | |
| HRP20150815T1 (hr) | Stabilna formulacija injektibilnog paracetamola spremna za uporabu | |
| JP2011504457A5 (ja) | ||
| BR112013004275A2 (pt) | glicodendrímeros de polipropileterimina | |
| PT1976538E (pt) | Formulação farmacêutica para o tratamento de artrose que contém ácido clodrónico e ácido hialurónico | |
| TR200909785A1 (tr) | Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar. | |
| MX2009005182A (es) | Derivados de 2-hidroxi-1,3-diamino-propano. |